Octocog alfa Kogenate For the treatment and prophylaxis of CSL (bhk) FS bleeding in patients with haemophilia A Behring (congenital Factor VIII deficiency). It may also be used in patients with Factor VIII inhibitors (neutralising antibodies) who continue to respond to infused Factor VIII. Kogenate FS does not contain von Willebrand Factor and is not indicated in von Willebrand’s disease. Octocog alfa Kovaltry Treatment and prophylaxis of bleeding in Bayer (bhk) patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups. (See Clinical Trials section). Kovaltry does not contain von Willebrand factor and is not indicated in von Willebrand disease. Octocog alfa For use in haemophilia A (classical Baxalta (rch) haemophilia) for the prevention and control of haemorrhagic episodes. Patients with haemophilia A may be treated with Recombinate as perioperative management. Recombinate is not indicated in von Willebrand’s disease. Moroctocog Xyntha For the control and prevention of Pfizer alfa haemorrhagic episodes in patients with haemophilia A, including control and prevention of bleeding in surgical settings. Xyntha does not contain von Willebrand factor and should not be used by patients with von Willebrand’s disease. Turoctocog alfa NovoEight For the treatment and prophylaxis of Novo bleeding episodes in patients with Nordisk haemophilia A, including control and prevention of bleeding in surgical settings. Simoctocog alfa Nuwiq Treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (> 2 years) and adult patients with haemophilia A (congenital factor VIII deficiency). Nuwiq does not contain von Willebrand Factor and is thus not indicated to treat von Willebrand's Disease.
Octocog alfa (bhk) Kogenate FS For the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital Factor VIII deficiency). It may also be used in patients with Factor VIII inhibitors (neutralising antibodies) who continue to respond to infused Factor VIII. Kogenate FS does not contain von Willebrand Factor and is not indicated in von Willebrand’s disease. CSL Behring Octocog alfa (bhk) Kovaltry Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Kovaltry can be used for all age groups. (See Clinical Trials section). Kovaltry does not contain von Willebrand factor and is not indicated in von Willebrand disease. Bayer Octocog alfa (rch) For use in haemophilia A (classical haemophilia) for the prevention and control of haemorrhagic episodes. Patients with haemophilia A may be treated with Recombinate as perioperative management. Recombinate is not indicated in von Willebrand’s disease. Baxalta Moroctocog alfa Xyntha For the control and prevention of haemorrhagic episodes in patients with haemophilia A, including control and prevention of bleeding in surgical settings. Xyntha does not contain von Willebrand factor and should not be used by patients with von Willebrand’s disease. Pfizer Turoctocog alfa NovoEight For the treatment and prophylaxis of bleeding episodes in patients with haemophilia A, including control and prevention of bleeding in surgical settings. Novo Nordisk Simoctocog alfa Nuwiq Treatment and prophylaxis of bleeding (also during and after surgery) in previously treated paediatric (> 2 years) and adult patients with haemophilia A (congenital factor VIII deficiency). Nuwiq does not contain von Willebrand Factor and is thus not indicated to treat von Willebrand's Disease.
auspar-lonoctocog-alfa-rch-180123.docx